The study, titled ‘Managing the mental state’ to tackle anxiety-related freezing of gait in people with Parkinson’s disease, set out to test a proposition that is increasingly supported by neuroscience but has rarely been evaluated in such a direct, trial-based fashion: that freezing of gait is not purely a motor problem, and that interventions aimed at the emotional and cognitive machinery of the brain may therefore yield measurable benefits for walking. The researchers framed their approach around the observation that anxiety and freezing tend to travel together, with anxious arousal narrowing attention, disrupting the automatic flow of movement and making episodes more likely at precisely the moments when people with Parkinson’s can least afford them.

Freezing of gait affects a substantial proportion of people with Parkinson’s as the disease progresses, and its mechanisms remain only partially understood. Contemporary models describe it as arising from a breakdown in the neural circuits that normally allow walking to proceed on autopilot. In healthy individuals, gait is largely controlled by subcortical loops that require little conscious attention. Parkinson’s disease damages these loops, forcing patients to rely more heavily on deliberate, effortful control of stepping. That compensation works reasonably well in calm, open environments, but it collapses under pressure. When cognitive resources are consumed by worry, when a doorway or a crowd demands rapid navigation, or when the fear of freezing itself takes hold, the fragile control system is overwhelmed and the gait pattern fragments into the characteristic stuttering, shuffling or complete arrest that patients know so well.

Anxiety enters this picture at several levels. There is the situational anxiety of approaching a feared trigger, such as turning in a tight space or crossing a busy road. There is the anticipatory anxiety that builds as people begin to organize their lives around avoiding situations in which freezing might occur, a pattern that can shrink confidence and mobility over time. And there is the physiological arousal that accompanies anxious states — elevated heart rate, muscle tension and heightened vigilance — all of which alter the way the brain allocates attention to movement. Researchers have argued that this arousal effectively competes with the already-strained motor control resources of the Parkinsonian brain, lowering the threshold at which freezing is triggered.

If anxiety is a genuine driver of freezing rather than a mere byproduct, the reasoning goes, then teaching patients to manage that anxiety should reduce the frequency or severity of episodes. This is the hypothesis the randomized controlled trial was designed to test. Rather than focusing on the mechanics of stepping, as many gait rehabilitation programs do, the intervention centered on strategies for regulating the mental state: recognizing the early signs of anxious arousal, applying techniques to calm and refocus attention, and reframing the fear of freezing that can itself precipitate an episode. Participants were randomly assigned to receive the mental-state intervention or a comparison condition, allowing the researchers to separate the specific effects of the anxiety-focused approach from the general benefits of attention, practice and clinical contact.

The randomized design matters. Freezing of gait fluctuates naturally from day to day and responds strongly to context, expectation and environment, which makes uncontrolled observations notoriously unreliable. A patient who believes a therapy will help may walk more confidently, freeze less and attribute the change to the treatment, regardless of the treatment’s specific content. By randomly allocating participants and including a comparator, the trial aimed to isolate the true effect of managing the mental state from placebo responses, regression to the mean and the natural course of the disease. Such rigor is essential if anxiety-focused approaches are to earn a place alongside medication, deep brain stimulation and cueing strategies in the standard toolkit for gait problems in Parkinson’s.

The broader significance of the trial lies in what it says about the nature of Parkinson’s disease itself. For much of the twentieth century, Parkinson’s was understood primarily as a disorder of movement, defined by tremor, rigidity, slowness and postural instability. Research over recent decades has progressively widened that picture, revealing profound non-motor dimensions — sleep disturbance, loss of smell, cognitive change, depression and anxiety — that often precede the motor symptoms by years and shape quality of life at least as much. The recognition that anxiety is not simply an understandable reaction to a difficult diagnosis but a modifiable factor with a direct bearing on motor function represents a meaningful shift. It reframes the psychological life of the patient as part of the disease mechanism, and therefore as a legitimate target of treatment.

The trial also speaks to a practical reality of clinical care. Pharmacological options for freezing of gait are limited; dopaminergic medications help some patients some of the time, but freezing frequently persists or even worsens as the disease advances, and no drug is approved specifically for the symptom. Physiotherapy and cueing techniques — rhythmic auditory signals, visual targets on the floor, laser attachments to walking frames — offer genuine benefit by providing external rhythm and attentional anchors, yet they do not address the internal state that can override them. An approach that equips patients to regulate anxiety in the moment could, in principle, be combined with these existing strategies, giving people a layered set of defenses: environmental cues for the feet, mental strategies for the mind.

For patients and families, the message embedded in this research is one of agency. Freezing of gait can feel arbitrary and humiliating, an unpredictable betrayal by one’s own body. The idea that the mental state — the breath, the attention, the fearful anticipation — is not just a victim of freezing but a participant in it offers a handle on the problem. It suggests that the moments before an episode, when the heart begins to race and the mind fills with dread, are not merely a prelude but an intervention point. Learning to notice that moment, and to act on it, may be as therapeutically important as any exercise performed in a clinic.

Much remains to be established. The mechanisms linking anxiety to freezing are still being mapped, the durability of mental-state interventions over months and years is an open question, and the optimal way to integrate such training with medication and physical therapy has yet to be defined. But the trial marks a clear step in a direction that many in the field consider overdue: treating the person with Parkinson’s as an integrated system in which emotion, cognition and movement are inseparable. If managing the mental state proves to loosen the grip of freezing, it will validate a simple but powerful idea — that in Parkinson’s disease, the mind is not a bystander to the gait, but part of the machinery that keeps it moving.

Subject of Research: A randomized controlled trial of mental-state management to reduce anxiety-related freezing of gait in Parkinson's disease.

Article Title: ‘Managing the mental state’ to tackle anxiety-related freezing of gait in people with Parkinson’s disease: a randomized controlled trial

Article References: Vissers, G., Tosserams, A., Duits, A. A., Helmich, R. C., Bloem, B. R., Young, W. R., & Nonnekes, J. (2026). ‘Managing the mental state’ to tackle anxiety-related freezing of gait in people with Parkinson’s disease: a randomized controlled trial. npj Parkinson's Disease. https://doi.org/10.1038/s41531-026-01571-w

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01571-w

Keywords: Parkinson's disease, freezing of gait, anxiety, randomized controlled trial, gait rehabilitation, motor symptoms, mental state, npj Parkinson's Disease, neurodegeneration, clinical trial, movement disorders, anxiety management

The Wilson and Cleary framework, first proposed in the 1990s and later revised, is one of the most influential conceptual models in outcomes research. It links biological and physiological variables through symptom status and functional health to general health perceptions and, ultimately, overall quality of life. What makes the model useful is its insistence on pathways: it does not simply ask which factors correlate with quality of life, but proposes directional chains through which disease mechanisms are translated into lived experience. Applying this revised model to Parkinson’s disease allowed the study’s authors to test, in a structured and statistically explicit way, which determinants carry the greatest weight along that chain.

Parkinson’s disease is the second most common neurodegenerative disorder worldwide, and its non-motor burden is increasingly recognized as a dominant driver of disability. Depression, anxiety, apathy, sleep disturbance, pain, fatigue, and sexual dysfunction are all more prevalent in Parkinson’s than in age-matched populations, and each has been independently associated with poorer quality of life in prior work. What has been missing, the researchers argue, is an integrated, multidimensional account that places these factors in a single explanatory architecture, rather than treating them as isolated contributors measured one at a time.

The study assembled a battery of validated instruments capturing the model’s successive levels: physiological measures and clinical characteristics of the disease, symptom scales covering both motor and non-motor domains, functional assessments, mental health measures including depressive and anxiety symptoms, and dedicated evaluation of sexual health. Quality of life was assessed with disease-specific and generic instruments, allowing the authors to examine both overall health perceptions and broader life evaluation. Statistical modeling then quantified the direct and indirect effects of each determinant, revealing how influences propagate from biological dysfunction through symptoms and function to the way patients judge their own health.

The headline finding is striking in its simplicity: mental health and sexual function emerged as determinants of quality of life comparable in importance to, and in some pathways stronger than, the classical motor measures that dominate routine neurological assessment. Depressive symptoms in particular acted as a powerful hub, both directly reducing quality of life and mediating the effects of other clinical variables. Sexual dysfunction, which affects a substantial proportion of both men and women with Parkinson’s disease, contributed significantly to poorer health perceptions even after accounting for disease severity, age, and functional status. The authors emphasize that these are not peripheral complaints but central components of the patient experience.

The pathway structure of the revised model proved illuminating. Motor severity influenced quality of life partly through its effect on symptoms and daily functioning, but also through its impact on mood, illustrating an indirect route in which physical decline erodes emotional well-being, which in turn depresses overall life evaluation. Conversely, some non-motor symptoms exerted effects that were largely mediated by mental health, suggesting that psychological state functions as a gateway through which much of the disease’s subjective burden passes. This mediation pattern has practical implications: interventions targeting depression and anxiety may ameliorate the quality-of-life consequences of a range of otherwise distinct symptoms.

Sexual health deserves particular attention in this framework. Sexual dysfunction in Parkinson’s disease arises from a convergence of mechanisms, including dopaminergic degeneration affecting autonomic and limbic circuits, medication effects, motor limitations, relationship strain, and psychological factors. The study’s finding that sexual function retains a significant association with quality of life within a multidimensional model underscores that it is an independent dimension of health, not merely a byproduct of depression or disability. Yet sexual health remains one of the least discussed topics in routine Parkinson’s care, with patients frequently reluctant to raise it and clinicians rarely asking. The authors suggest that structured assessment of sexual function should be incorporated into comprehensive care pathways.

The multidimensional approach also highlights the interdependence of domains often managed by different specialists. Sleep problems feed fatigue; fatigue erodes physical activity; inactivity worsens mood and function; and each step along the chain degrades health perceptions. By modeling these relationships simultaneously, the revised Wilson and Cleary framework provides a map of where interventions might yield the greatest downstream benefit. Treating depression, optimizing dopaminergic therapy, addressing sexual dysfunction, supporting physical function, and attending to social and role functioning are not competing priorities but complementary leverage points on a shared causal network.

For clinicians, the message is that quality of life in Parkinson’s disease is not a simple readout of motor state. Two patients with comparable disease duration and comparable Unified Parkinson’s Disease Rating Scale scores may inhabit radically different subjective worlds depending on their mood, their intimate relationships, and their ability to sustain valued activities. Routine care that measures only the visible layer of the disease risks systematically underestimating the burden carried by those whose motor symptoms are well controlled but whose emotional, sexual, and social health is not. Screening instruments for depression, anxiety, and sexual function are brief, validated, and inexpensive, making systematic implementation feasible in ordinary outpatient settings.

For researchers, the study demonstrates the value of theory-driven models in a field awash with correlational data. Rather than cataloguing associations, the revised Wilson and Cleary model imposes an ordered structure that can be tested, refined, and compared across conditions and populations. The authors note that longitudinal designs will be needed to confirm the directional pathways suggested here, and that interventions designed with the model in mind, for example psychotherapy or sexual health counseling embedded within neurological care, could provide direct tests of its practical utility. If subsequent trials confirm that improving mental and sexual health yields measurable gains in overall quality of life beyond what motor optimization achieves, the study will have helped shift the center of gravity in Parkinson’s care toward a genuinely holistic medicine, one that treats patients not as motors to be tuned but as whole people whose intimacy, mood, and dignity are inseparable from their health.

Subject of Research: Determinants of health-related quality of life in Parkinson's disease, including sexual and mental health, analyzed with the revised Wilson and Cleary model

Article Title: Sexual, mental, and multidimensional determinants of health-related quality of life in Parkinson's disease using the revised Wilson and Cleary model

Article References: Alenko, A., Sudhakar, M., Chelkeba, L., Fomenko, E., & Keygnaert, I. (2026). Sexual, mental, and multidimensional determinants of health-related quality of life in Parkinson's disease using the revised Wilson and Cleary model. Scientific Reports. https://doi.org/10.1038/s41598-026-71122-z

Image Credits: AI Generated

DOI: 10.1038/s41598-026-71122-z

Keywords: Parkinson's disease, quality of life, Wilson and Cleary model, sexual dysfunction, mental health, depression, non-motor symptoms, health-related quality of life, neurodegenerative disease, patient outcomes, Sexual, mental